SCHEMBL10181508

SCHEMBL10181508

CC(F)(F)c1cccc(-c2noc(-c3nnn(-c4ccccc4F)c3-c3ccncc3)n2)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 5/20 0.51
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
MAPT P10636 3/20 0.43
TP53 P04637 5/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.40
KMT2A Q03164 1/20 0.40
S1PR3 Q99500 4/20 0.40
RXFP1 Q9HBX9 1/20 0.39
NR1H4 Q96RI1 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3755472 0.93 NPC1 (0.56) S1PR1NPC1RAB9AMAPTTP53
SCHEMBL10182728 0.90 NPC1 (0.45) S1PR1NPC1RAB9AMAPTTP53
SCHEMBL3752775 0.87 S1PR1 (0.54) S1PR1NPC1RAB9AMAPTTP53
SCHEMBL3761171 0.87 MAPT (0.54) S1PR1NPC1RAB9AMAPTTP53
SCHEMBL3763529 0.87 TP53 (0.55) S1PR1NPC1RAB9AMAPTTP53
SCHEMBL3760855 0.86 NPC1 (0.52) S1PR1NPC1RAB9AMAPTTP53
SCHEMBL3761084 0.86 NPC1 (0.54) S1PR1NPC1RAB9AMAPTTP53
SCHEMBL3753246 0.85 NPC1 (0.54) S1PR1NPC1RAB9AMAPTTP53
SCHEMBL3760339 0.85 S1PR1 (0.51) S1PR1NPC1RAB9AMAPTTP53
SCHEMBL3756298 0.85 NPC1 (0.47) S1PR1NPC1RAB9AMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES OXA1L, RO60, PDCD11 S1PR1 517/4885NPC1 4730/4885RAB9A 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.